Your new experience awaits. Try the new design now and help us make it even better

CASE REPORT article

Front. Oncol.

Sec. Gynecological Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1614373

This article is part of the Research TopicGynecological Cancer Prevention in Women with Inherited Genetic RiskView all articles

Clinical Impact of BRCA1 and BRIP1 vs. BRCA1 and BRCA2 Germline Double Heterozygosity in Ovarian Cancer: A Comparative Case Study

Provisionally accepted
  • 1Department of Obstetrics and Gynecology in Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province,, Hangzhou, Jiangsu Province, China
  • 2Polytechnic Institute, Zhejiang University, Hangzhou, Zhejiang Province, China
  • 3Center for Clinical Genetics and Genomics, DIAN Diagnostics, Hangzhou, 310058, Zhejiang, China, Hangzhou, China
  • 4DIAN Diagnostics, Hangzhou, 310058, Zhejiang, China, hangzhou, China
  • 5Center for Precision Medicine, Zhejiang-California International NanoSystems Institute, Hangzhou, Jiangsu Province, China
  • 6Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York, United States

The final, formatted version of the article will be published soon.

Ovarian cancer (OC) is a highly heterogeneous malignancy influenced by germline genetic factors, with BRCA1/2 mutations being well-established risk factors. Germline double heterozygosity (GDH), particularly involving rare combinations, remains poorly understood. This study presents the first report of BRCA1/BRIP1 GDH in a case of Chinese OC patients and compares their clinical characteristics and treatment responses to a patient with BRCA1/BRCA2 GDH. The BRCA1/BRIP1 GDH patient is a 46-year-old female diagnosed with advanced ovarian adenocarcinoma at clinical stage FIGO IVB, exhibited severe chemotherapy-induced toxicity and postoperative complications, including chylous leakage. In contrast, the BRCA1/BRCA2 GDH patient is a 44-year-old female with high-grade serous ovarian cancer at clinical stage FIGO IIIC, tolerated chemotherapy well. Both patients experienced clinical benefit from Olaparib maintenance therapy. Genetic testing confirmed pathogenic variants in both cases, revealing distinct clinical trajectories influenced by different GDH profiles. Our findings suggest that different GDH combinations may influence chemotherapy tolerance and therapeutic effectiveness in OC. BRCA1/BRIP1 GDH patients may require personalized dose adjustments to mitigate toxicity and optimize efficacy. This study underscores the clinical significance of GDH heterogeneity and the importance of comprehensive genetic testing for guiding individualized treatment strategies. Future research should focus on expanding sample sizes and conducting in-depth functional analyses to further clarify the clinical implications of different GDH types, ultimately refining treatment approaches for GDH-associated OC.

Keywords: BRCA1, BRCA2, BRIP1, germline double heterozygosity, ovarian cancer, case report

Received: 18 Apr 2025; Accepted: 04 Jul 2025.

Copyright: © 2025 Zheng, Zhu, Zhang, Qiu, Qin, Yang and Qi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
Jianhua Yang, Department of Obstetrics and Gynecology in Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province,, Hangzhou, Jiangsu Province, China
Ming Qi, Department of Obstetrics and Gynecology in Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Key Laboratory of Reproductive Dysfunction Management of Zhejiang Province,, Hangzhou, Jiangsu Province, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.